ProCE Banner Activity

Safeguarding the Future of HIV Care at CROI 2025: Advances in LA ART and LA PrEP

Conference Coverage
Clinical Thought

Learn how studies presented at CROI 2025 suggest that bNAbs combined with lenacapavir could play a role in providing further options for long-acting HIV treatment, and perhaps even ART-free viral control.

Released: May 07, 2025

Expiration: May 06, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Faculty Disclosure

Primary Author

Sharon R. Lewin, AO, FRACP, PhD, FAA, FAHMS: consultant/advisor/speaker: AbbVie, Esfam, Gilead.